L3VLUP
ProSign in

KRYS in the 13F filings

Krystal Biotech Inc · CUSIP 501147102

Sector · Pharmaceuticals and biotechnologyTheme · Biological productsTheme · Healthcare: biopharma and medtech· L3VLUP-defined
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023Q3 2023
Quarter end
30 Sep 2023
the date the book describes
Filed
14 Nov 2023
latest of these filings; the earliest 14 Nov 2023
Managers listing it
5
at least, of 95 tracked, among listed positions
Comparable managers
93
filed both Q2 2023 and Q3 2023; 3 listed it in both
Shares listed
1,232,807
combined, among listed positions
Reported value
$143m
combined, at the quarter end

Managers listing KRYS in Q3 2023

Share of 13F value is the position’s reported value over everything the manager reported that quarter. The share change is against Q2 2023, and only where both filings list the position. A rise in value with no rise in shares is the price, not buying.

5 of 5 holders

ActionFiling
Point72 Asset Management LP698,158$81m0.24%Added+138,89714 Nov 2023 (the filing on sec.gov)
Woodline Partners LP321,944$37m0.44%Added+277,72114 Nov 2023 (the filing on sec.gov)
Verition Fund Management LLC127,070$15m0.17%Added+35,33814 Nov 2023 (the filing on sec.gov)
Schonfeld Strategic Advisors LLC83,635$9.7m0.08%Addedn.a.14 Nov 2023 (the filing on sec.gov)
Farallon Capital Management LLC2,000$232kunder 0.1%Newnew14 Nov 2023 (the filing on sec.gov)

Largest increases and reductions, by shares

Q2 2023 to Q3 2023, among managers that listed it in both quarters or opened it.

Increases

Reductions

No reduction among listed positions.

New positions and exits

At least these many: a manager is shown exiting only where its own filing shows the position gone.

New (1)

Exited (0)

No exit shown by a manager’s own filing.

Ownership over time

Every quarter on file. A quarter-end value moves with the price as well as with the shares held; buyers and sellers count comparable managers, by shares.
5 in Q3 2024 to 6 in Q2 2026

Tracked managers listing it, at least.

0246820192020202120222023202420252026
the quarter shown share split complete books; unmarked quarters rest on listed positionsClick a quarter to open it.
KRYS by quarter
QuarterHoldersReported valueBuyersSellers
Q4 20181$260kn.a.n.a.
Q1 20191$581kn.a.n.a.
Q2 20191$2.5mn.a.n.a.
Q3 20191$2.4mn.a.n.a.
Q4 20191$1.3mn.a.n.a.
Q1 20202$15mn.a.n.a.
Q2 20204$45mn.a.n.a.
Q3 20204$52mn.a.n.a.
Q4 20203$66mn.a.n.a.
Q1 20213$67mn.a.n.a.
Q2 20212$28mn.a.n.a.
Q3 20212$31mn.a.n.a.
Q4 20212$135mn.a.n.a.
Q1 20221$114mn.a.n.a.
Q2 20222$107mn.a.n.a.
Q3 20223$97mn.a.n.a.
Q4 20223$59mn.a.n.a.
Q1 20233$59mn.a.n.a.
Q2 20233$82mn.a.n.a.
Q3 20235$143mn.a.n.a.
Q4 20235$109m31
Q1 20248$853m52
Q2 20246$1.0bn50
Q3 20245$976m31
Q4 20245$850m40
Q1 20255$993m40
Q2 20254$746m12
Q3 20255$938m21
Q4 20257$1.4bn1311
Q1 20266$1.5bn1511
Q2 20266$2.4bn1214

Compare with…

Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.

KRYS and GILD →KRYS and AMGN →KRYS and ARGX →Choose a stock to compare with KRYS →

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.

Which funds own KRYS, latest filings →Back to the 13F Explorer →